• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Agilent to Announce Fourth-Quarter Fiscal Year 2024 Financial Results on Nov. 25

    10/16/24 4:30:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Agilent Technologies Inc. (NYSE:A) will release financial results for the fourth quarter of fiscal year 2024 after the stock market closes on Monday, Nov. 25. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST.

    To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days.

    About Agilent Technologies

    Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241016558200/en/

    Get the next $A alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When will Agilent Technologies Inc. release their fourth quarter financial results for fiscal year 2024?

      Agilent Technologies Inc. is expected to release their financial results after the stock market closes on November 25, 2024.

    • What time is the conference call to discuss Agilent's fourth quarter financial results scheduled?

      Agilent's conference call to discuss their financial results will be held at 1:30 p.m. PST.

    • How can investors and interested parties listen to Agilent's conference call on the financial results?

      The conference call webcast can be accessed by clicking the link in the Events section of Agilent's investor relations website.

    • What was Agilent Technologies Inc.'s revenue for fiscal year 2023?

      Agilent Technologies Inc. generated revenue of $6.83 billion in fiscal 2023.

    • How many employees does Agilent Technologies Inc. have, and what industry do they operate in?

      Agilent employs approximately 18,000 people worldwide and is a leader in analytical and clinical laboratory technologies.

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agilent to Showcase New Products and Innovations at HPLC 2025

      Agilent Technologies Inc. (NYSE:A) today announced that they will introduce their latest Hybrid Multisampler and highlight the new LC Single Quadrupole Mass Spectrometers at the upcoming HPLC 2025 conference in Bruges, Belgium. These new additions are designed to boost laboratory efficiency and deliver superior results. Exhibition attendees will be able to see how these products can streamline operations and enhance analytical outcomes. The Agilent InfinityLab Pro iQ Series, launched at ASMS 2025, represents the next generation of LC-mass detection. With innovative hardware advancements, the series delivers enhanced sensitivity and analytical performance for oligonucleotides, therapeutic

      6/12/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Smackover Lithium's South West Arkansas Project Receives Royalty Rate Approval From the Arkansas Oil and Gas Commission

      LEWISVILLE, Ark., May 29, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the Arkansas Oil and Gas Commission ("AOGC") has unanimously approved the establishment of a 2.5% royalty rate for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties. This is the first royalty rate for lithium from brine extraction that has been approved by the AOGC, establishing an important precedent for lithium development companies operating in Arkansas. SWA Lithium LLC applied for a quarterly gross royalty of

      5/29/25 8:30:27 AM ET
      $A
      $SLI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Major Chemicals
    • Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

      Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

      5/28/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials